Glucosamine Containing Patents (Class 536/55.2)
  • Patent number: 10227368
    Abstract: The invention relates to an efficient and reproducible process for generating glucosamine from plants which allows high glucosamine content to be obtained while reducing the content of residual ammonium or sulfate ions. The invention also concerns food compositions or cosmetic compositions which comprise the obtained glucosamine-enriched plant compositions.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: March 12, 2019
    Assignee: Nestec S.A.
    Inventors: Jwanro Husson, Didier Courtois
  • Patent number: 9518078
    Abstract: Essentially pure compounds of the formulas (I) to (XXV) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: December 13, 2016
    Assignees: Avanti Polar Lipids, Inc., AC Immune SA
    Inventors: Walter A Shaw, Stephen W Burgess, Shengrong Li, David T Hickman, Maria Pilar Lopez-Deber
  • Patent number: 9241988
    Abstract: Essentially pure compounds of the formulas (I) to (XX) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: January 26, 2016
    Assignees: AVANTI POLAR LIPIDS, INC., AC IMMUNE SA
    Inventors: Walter A Shaw, Stephen W Burgess, Shengrong Li, David T Hickman, Maria Pilar Lopez-Deber
  • Patent number: 8951990
    Abstract: Described herein are methods for treating a dental disorder in a subject comprising administering to the subject an effective amount of a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and the primary C-6 hydroxyl proton of at least one N-acetyl-glucosamine residue is substituted with a C1-C10 unsubstituted alkyl group or fluoroalkyl group.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: February 10, 2015
    Assignee: University of Utah Research Foundation
    Inventors: Glenn Prestwich, Jianxing Zhang, Sr., Thomas P. Kennedy, Narayanam Rao
  • Patent number: 8940888
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: January 27, 2015
    Assignee: Prochon Biotech Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Publication number: 20150018522
    Abstract: Disclosed are mutants of galactosyltransferases that can catalyze formation of oligosaccharides in the presence of magnesium; mutants of galactosyltransferases having altered donor and acceptor specificity which can catalyze formation of oligosaccharides in the presence of magnesium; methods and compositions that can be used to synthesize oligosaccharides; methods for increasing the immunogenicity of an antigen; and methods to stabilize platelets.
    Type: Application
    Filed: March 10, 2014
    Publication date: January 15, 2015
    Applicant: The United States of America, as represented by the Secretary, Department of Health & Human Servic
    Inventors: Pradman K. Qasba, Elizabeth Boeggeman, Boopathy Ramakrishnan
  • Publication number: 20140378679
    Abstract: ?-Lactosamine hydrochloride, substantially free of ?-lactosamine hydrochloride; a method of preparing ?-lactosamine hydrochloride monohydrate from an anomeric mixture of lactosamine hydrochloride, including: preparing a solution including the anomeric mixture of lactosamine hydrochloride, water and at least one water-miscible organic solvent at a temperature of 0-100° C., and cooling the solution to cause crystallisation of ?-lactosamine hydrochloride monohydrate; a method of preparing anhydrous ?-lactosamine hydrochloride; and use of ?-lactosamine hydrochloride as a food supplement or intermediate in synthesis.
    Type: Application
    Filed: July 1, 2014
    Publication date: December 25, 2014
    Applicant: GLYCOM A/S
    Inventors: Gyula DEKANY, Károly ÁGOSTON, István BAJZA, Marie BØJSTRUP, Ignacio FIGUEROA PÉREZ, Lars KRÖGER, Christoph H. RÖHRIG
  • Patent number: 8900576
    Abstract: The present invention concerns new compositions containing hyaluronic acid or the derivatives thereof in association with the proteolytic enzyme collagenase (and relative pharmaceutical formulations) for the preparation of a dressing for topical treatment of various kinds of wounds, burns of varying depth, pressure sores, vascular ulcers and diabetic foot ulcers as well as for the treatment of hypertrophic and keloid scars.
    Type: Grant
    Filed: July 5, 2006
    Date of Patent: December 2, 2014
    Assignee: Fidia Farmaceutici S.p.A
    Inventors: Susanna Vaccaro, Giovanni Gennari, Lanfranco Callegaro, Antonio Giannelli, Salvatore Caruso
  • Patent number: 8901103
    Abstract: This invention provides a method of treating a subject suffering from a dermatologic condition, including, inter alia, psoriasis, contact dermatitis, and seboreic dermatitis, the method includes the step of administering to a subject a compound comprising a lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof, in an amount effective to treat the subject suffering from a dermatologic condition.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: December 2, 2014
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventor: Saul Yedgar
  • Patent number: 8871744
    Abstract: The present invention relates to pharmaceutical compositions containing tumor-selective targeted inhibitor glycoconjugates. These bioconjugates are ALK5 inhibitors covalently bound to biocompatible carrier molecules which selectively target and specifically bind to Muc4 that is overexpressed on a variety of tumor cell types. The ALK5 inhibitors are conjugated to tumor targetable glycans through a covalent linker. Preferably the acid-labile linker is designed to be stable in plasma and releases pharmacologically active inhibitors through acid-catalyzed hydrolysis in the acidic environment of the target tumor where the inhibitor activity is restored. Because the glycoconjugates are stable at physiological pH and in plasma, they advantageously reduce undesirable systemic ALK5 inhibitor activity; however, the preferable glycoconjugates are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 28, 2014
    Assignee: B & G Partyers, LLC
    Inventor: Donald L. Barbeau
  • Patent number: 8802841
    Abstract: A 1,2-dideoxy-1,2-diamino oligosaccharide or polysaccharide in its free base, salt or metal-complex form as shown in General Formula 1 and derivative thereof is described. R1, R2 and R3 are each independently selected from the group consisting of H and a carbohydrate moiety, with the proviso that at least one of the groups R1, R2 or R3 is a carbohydrate moiety; R4 is selected from the group consisting of: H, optionally substituted C1-20-alkyl, optionally substituted heteroalkyl, optionally substituted C2-20-alkenyl, optionally substituted C2-20-alkynyl, optionally substituted C3-10-cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: August 12, 2014
    Assignee: Glycom A/S
    Inventors: Gyula Dekany, István Bajza, Marie Bøjstrup, Károly Ágoston, Lars Kröger, Ignacio Figueroa Pérez, Christoph H. Röhrig, Paulo Vital, Erzsébet Czinege
  • Patent number: 8785621
    Abstract: A malleable compound according to the invention for use as a disinfectant comprises water, 25 to 40% by weight of a solvent component comprising low-molecular, water-miscible alcohols, 1 to 10% by weight of an active bactericidal component, 3 to 6% by weight hydroxypropylated polygalactomannan with an etherification level of between 0.3 and 1.5 and 0.1 to 0.5% by weight boracic acid or an equivalent amount of boron ions.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: July 22, 2014
    Assignee: Joker AG
    Inventors: Meinrad Flury, Rene H. Dietrich
  • Patent number: 8778892
    Abstract: The present invention relates to pharmaceutical compositions containing targetable bioconjugates of hydralazine, a direct vasodilating agent previously shown to decrease tumor blood flow, oxygenation and interstitial fluid pressure in solid tumors. These bioconjugates are hydralazine prodrugs that contain hydralazine conjugated to biocompatible carrier molecules which specifically bind to sites that are expressed on a diverse variety of tumor cell types. These hydralazine prodrugs are preferably conjugated through an acid-labile hydrazone link that is designed to be stable in plasma and release hydralazine through acid-catalyzed hydrolysis in the acidic environment of the target tumor. Because these prodrugs are stable at physiological pH and in plasma, they are devoid of systemic vasoactive activity; however, they are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor where the vasoactive activity of hydralazine is restored.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: July 15, 2014
    Assignee: B & G Partners, LLC
    Inventor: Donald L. Barbeau
  • Patent number: 8748409
    Abstract: Disclosed are a polysaccharide derivative obtained by substituting some of the carboxyl groups of a carboxy polysaccharide with —NH—X—CO—Y—Z; and a hydrogel thereof. Here, X is a C1-10 hydrocarbon group, Y is a polyalkylene oxide having oxygen atoms at both ends, and Z is a C1-24 hydrocarbon group or —CO—R2, with R2 being a C1-23 hydrocarbon group. The hydrogel has excellent viscoelasticity and can be injected into a predetermined location with an injection device such as a syringe, and thus can be advantageously used as a medical gel or an adhesion barrier.
    Type: Grant
    Filed: April 19, 2010
    Date of Patent: June 10, 2014
    Assignee: Teijin Limited
    Inventors: Hiroaki Kaneko, Masaya Ito
  • Publication number: 20140107068
    Abstract: A marker can determine whether or not a patient has a therapeutic response to an anti-cancer agent. A novel cancer therapy employs the marker. The marker can be N-acetylglucosamine, an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, lauric acid, 6-phosphogluconic acid, butyric acid, 4-methylpyrazole, isobutylamine, glycolic acid, NADH, NAD+, or a substance involved in the metabolism of any of these substances.
    Type: Application
    Filed: February 24, 2012
    Publication date: April 17, 2014
    Applicants: KABUSHIKI KAISHA YAKULT HONSHA, KEIO UNIVERSITY
    Inventors: Yusuke Tanigawara, Akito Nishimuta, Yuki Otani, Mitsuhisa Matsuo
  • Patent number: 8691957
    Abstract: The present invention is provides a crosslinked hyaluronan powder excellent in swellability in water and a method for simply producing the same. A method for producing the swellable crosslinked hyaluronan powder is characterized by comprising mixing a crosslinking agent with a hyaluronan powder in a state dispersed in a liquid medium containing a monovalent alcohol having 1 to 4 carbon atoms and a solubility of the hyaluronan powder of less than 0.1 g/L to cause a crosslinking reaction. Also, the swellable crosslinked hyaluronan powder produced by the method has a swelling ratio in water of 500% or more.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: April 8, 2014
    Assignee: Shiseido Company, Ltd.
    Inventor: Tetsunori Matsumoto
  • Patent number: 8653049
    Abstract: The invention provides a compound (which can act as an adjuvant) of Formula I or Formula (II), wherein R1 R4 R5 R6 and R7 are each independently selected from hydrogen, acetyl, hydrocarbyl, a lipid moiety and a lipid acyl moiety; R2 is a hydroxyl, a hydrocarbyl, a lipid moiety, a lipid acyl moiety; or an amino hydrocarbyl group optionally substituted with a hydrocarbyl, a lipid moiety or a lipid acyl moiety; R3 and R8 are each independently selected from acetyl, a hydrocarbyl, a lipid moiety and a lipid acyl moiety; X is a peptide chain; The above normuramylglycopeptide compounds can be located in liposomes and micelles and can function as immunomodulators, along with a desired antigen (or DNA encloding the antigen), in (e.g. DNA) vaccines.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: February 18, 2014
    Assignees: Imuthes Limited, Institute of Organic Chemistry and Biochemistry AV CR, V.V.I., Vyzkumny USTAV Veterinarniho Lekarstvi, V.V.I.
    Inventors: Karsten Hipler, Andrew Miller, Jaroslav Turanek, Miroslav Ledvina
  • Publication number: 20140031312
    Abstract: Disclosed are compositions and formulations comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and adapted for use in a bath or soak or bath beads, powders, salts, and oils, kits, and methods of treatment using the same. Also disclosed are lozenges, suppositories, patches, and topical creams comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and methods of treatment using the same. In some embodiments the joint conditions include osteoarthritis.
    Type: Application
    Filed: March 12, 2013
    Publication date: January 30, 2014
    Applicant: Vital Medicine, LLC
    Inventors: Anjan Chatterji, Grant Cooper, David Schwartz
  • Publication number: 20130343995
    Abstract: Novel methods of synthesis of ethylenedicysteine-sugar conjugates and therapeutic and diagnostic applications of such conjugates are disclosed. Methods of synthesizing these conjugates in high purity are also presented as using starting materials such as thiazolidine carboxylic acid. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these conjugates prepared herein, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.
    Type: Application
    Filed: March 26, 2013
    Publication date: December 26, 2013
    Inventor: Board of Regents, The University of Texas System
  • Publication number: 20130337037
    Abstract: The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to treat wounds. More specifically the present invention relates to hemostatic compositions that reduce the need for, and cost of, nursing care of patients with chronic wounds by reducing the frequency of wound dressing changes.
    Type: Application
    Filed: July 31, 2013
    Publication date: December 19, 2013
    Applicant: Marine Polymer Technologies, Inc.
    Inventors: Sergio Finkielsztein, John N. Voumakis
  • Patent number: 8609835
    Abstract: The present invention relates to purification and use of a novel emulsion stabilizing polysaccharide. In particular, a polyelectrolyte exopolysaccharide with high molecular weight comprising a high molecular weight polymer with a tri-saccharide repeating unit is disclosed. In one aspect of the invention, methods are directed to isolating and purifying a high molecular weight exopolysaccharide (EPS) from a cell supernatant. In another aspect, methods are disclosed for isolating a lipopolysaccharide (LPS) and a high molecular weight Acinetobacter polyelectrolyte exopolysaccharide (APE) from Acinetobacter bacteria. Compositions are also directed to lipid nanoparticles comprising a therapeutic agent encapsulated by a high molecular weight polysaccharide and nanoparticles comprising a therapeutic agent bound to a cationic polysaccharide cross-linked with a polyanion.
    Type: Grant
    Filed: May 28, 2009
    Date of Patent: December 17, 2013
    Assignee: Trustees Of Tufts College
    Inventors: David L. Kaplan, Bruce Panilaitis, Michael Mercaldi, Hanna Dams-Kozlowska
  • Patent number: 8580951
    Abstract: Novel aldehyde-functionalized polysaccharide compositions are described that are more stable in aqueous solution than oxidized polysaccharides or other types of polysaccharides containing pendant aldehyde groups. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions.
    Type: Grant
    Filed: July 1, 2010
    Date of Patent: November 12, 2013
    Assignee: Actamax Surgical Materials, LLC
    Inventors: Helen S. M. Lu, Steven W. Shuey
  • Patent number: 8580950
    Abstract: Novel aldehyde-functionalized polysaccharide compositions containing pendant dialdehyde groups are described that are more stable in aqueous solution than oxidized polysaccharides. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: November 12, 2013
    Assignee: Actamax Surgical Materials, LLC
    Inventors: Helen S. M. Lu, Steven W. Shuey
  • Publication number: 20130288932
    Abstract: According to an embodiment, a method of providing a biopolymer comprises: cryodesiccating a broth, wherein the broth comprises: (A) a biopolymer, wherein the biopolymer is an exopolysaccharide; and (B) a liquid growth medium. According to certain embodiments, the biopolymer is produced by the fermentation of at least one carbohydrate via a microbe. According to an embodiment, the microbe is a bacterium. According to another embodiment, the microbe is a fungus.
    Type: Application
    Filed: April 27, 2012
    Publication date: October 31, 2013
    Applicant: HALLIBURTON ENERGY SERVICES, INC.
    Inventors: Andrew A.F. Mackenzie, Eric Davidson
  • Publication number: 20130281387
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
    Type: Application
    Filed: October 18, 2011
    Publication date: October 24, 2013
    Applicant: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
  • Patent number: 8536317
    Abstract: A process for producing a polysaccharide sponge comprises the steps of (A) freezing a photoreactive polysaccharide solution, and (B) irradiating the frozen photoreactive polysaccharide solution with light to crosslink the photoreactive polysaccharide, thereby obtaining the polysaccharide sponge. The process includes simplified steps requiring no removal of solvent, and has such an advantage that impurities are easily removed therefrom.
    Type: Grant
    Filed: December 29, 2010
    Date of Patent: September 17, 2013
    Assignee: Seikagaku Corporation
    Inventor: Tomoya Sato
  • Patent number: 8530450
    Abstract: Disclosed are acid polysaccharides characterized by the concomitant presence of alcohol groups esterified with butyric and formic acids.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: September 10, 2013
    Assignee: Sigea S.R.L.
    Inventors: Marco Bosco, Luca Stucchi, Rita Gianni, Antonia Trevisan
  • Patent number: 8524886
    Abstract: An outer layer having an entanglement comprising an intermingling of cloaked hydrophilic guest and a hydrophobic polymer host, wherein molecules of the guest have been crosslinked with each other. Under certain circumstances, using complexes of the guest may be desirable or even necessary. The intermingling of the guest and host includes a physical tangling, whether it also comprises crosslinking by primary bonding (e.g., chemical/covalent bonding) there-between. Also a method of producing an outer layer having such an entanglement, including the steps of: temporarily cloaking at least a portion of the hydrophilic groups of the guest; intermingling at least a portion of the cloaked groups with a porous polymeric structure by diffusing the guest with cloaked groups into at least a portion of the structure's pores; within the pores, crosslinking at least a portion of the molecules of the guest with the guest; and removing the cloaking. Cloaking may be performed by silylation or acylation.
    Type: Grant
    Filed: February 15, 2010
    Date of Patent: September 3, 2013
    Assignee: Colorado State University Research Foundation
    Inventors: Susan P. James, Min Zhang, Guy Beauregard
  • Patent number: 8524884
    Abstract: An outer layer material having an entanglement comprising an intermingling of cloaked hydrophilic guest and a hydrophobic polymer host, wherein molecules of the guest have been crosslinked with each other. Under certain circumstances, using complexes of the guest may be desirable or even necessary. Prior to intermingling with the guest, a host blend may be produced to include a physical blend of a hydrophobic polymer host and a maleated hydrophobic co-host (preferably, an anhydride functionalized hydrophobic polymer, whereby the polymer so functionalized, is the same as that selected for the host). The intermingling of the guest and host, or host-co-host blend, includes a physical tangling, whether it also comprises crosslinking by primary bonding (e.g., chemical/covalent bonding) there-between.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: September 3, 2013
    Assignee: Colorado State University Research Foundation
    Inventors: Susan P. James, Min Zhang, Guy Beauregard, Rachael Kurkowski Oldinski
  • Publication number: 20130116211
    Abstract: New salts or ion-pair complexes obtained by a reaction between boswellic acids or selectively enriched 3-O-acetyl-11-keto-?-boswellic acid (AKBA) or 11-keto-?-boswellic acid (KBA) compounds obtained through a new improved process, and an organic amine, more particularly with glucosamine. These salts or ion pair complexes are useful in nutraceuticals and in food supplements for anti-inflammatory and analgesic treatment of joints and cancer prevention or cancer therapeutic agents. These salts or ion pair complexes could also be used in cosmetic or pharmaceutical composition for external treatment of body parts or organs to treat inflammatory diseases or cancer.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 9, 2013
    Inventors: Ganga Raju Gokaraju, Rama Raju Gokaraju, Venkata Subbaraju Gottumukkala, Trimurtulu Golakoti, Venkateswarlu Somepalli
  • Patent number: 8404833
    Abstract: Preparation and use of synthetic disaccharides useful for the preparation of synthetic heparinoids.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: March 26, 2013
    Assignee: Alchemia Limited
    Inventors: Joachim Seifert, Latika Singh, Tracie E. Ramsdale, Michael L. West, Nicholas B. Drinnan
  • Patent number: 8394784
    Abstract: Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: March 12, 2013
    Assignee: Allergan, Inc.
    Inventors: Dimitrios Stroumpoulis, Dustin B. Leslie, Christopher S. Mudd, Ahmet Tezel
  • Patent number: 8389713
    Abstract: A photocrosslinked polysaccharide pseudo-sponge exhibiting a low swelling property and a high degradation ability in vivo while retaining a suitable strength. The polysaccharide pseudo-sponge is produced by a crosslinking reaction of a photoreactive polysaccharide obtained by introducing a photoreactive group into a polysaccharide, and exhibits a low swelling property and a blue dextran-low dyeaffinity.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: March 5, 2013
    Assignee: Seikagaku Corporation
    Inventor: Tomoya Sato
  • Patent number: 8378090
    Abstract: The present invention relates to a process for generating glucosamine from plants wherein fresh plant materials, or re-hydrated dried plant materials or plant extracts, are heated at a temperature comprised between 70 and 110° C. for more than 10 hours, characterized in that a fertilizer acting as glucosamine precursor is added during the cultivation of the plants, before the harvest.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: February 19, 2013
    Assignee: Nestec S.A.
    Inventors: Vincent Petiard, Stephane Michaux, Didier Courtois
  • Publication number: 20130035479
    Abstract: The present invention relates to a novel process for the chemical synthesis of ?-(1->6)-linked glucosamine disaccharides of the formula (1) and (intermediate) compounds relating to the process. According to further aspects the invention relates to compositions comprising the compounds and the use of the compounds in the synthesis of disaccharides and medicine.
    Type: Application
    Filed: October 1, 2012
    Publication date: February 7, 2013
    Applicant: OM PHARMA
    Inventor: OM PHARMA
  • Patent number: 8338386
    Abstract: The present invention relates to the prevention/treatment of ichthyosis vulgaris (IV), atopy and potentially other disorders associated with loss-of-function mutations in the filaggrin gene sequence. The prevention/therapy is based on the use of agents which enable the host's translational machinery to read through a nonsense mutation found in a mutant allele of the filaggrin gene.
    Type: Grant
    Filed: January 17, 2007
    Date of Patent: December 25, 2012
    Assignee: University Court of the University of Dundee
    Inventors: William Henry Irwin McLean, Frances Jane Dorothy Smith
  • Patent number: 8324356
    Abstract: Disclosed are polysaccharides containing residues of glucosamine or galactosamine in the repetitive unit, characterized by the presence of esters on the hydroxyls or amides on the amine functions, with lipoic acid or with mixtures of lipoic acid and formic acid.
    Type: Grant
    Filed: December 11, 2008
    Date of Patent: December 4, 2012
    Assignee: Sigea S.R.L.
    Inventors: Fabrizio Picotti, Marco Bosco, Luca Stucchi, Matteo Fabbian
  • Patent number: 8318697
    Abstract: Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: November 27, 2012
    Assignee: Corixa Corporation
    Inventors: David H. Persing, Richard Thomas Crane, Gary T. Elliott, J. Terry Ulrich, Michael J. Lacy, David A. Johnson, Jory R. Baldridge, Rong Wang
  • Patent number: 8314078
    Abstract: A silver nanocomposite, a formation method for forming the silver nanocomposite, and an application method utilizing the silver nanocomposite. The silver nanocomposite includes a silver nanoparticle conjugated to a glycosaminoglycan (GAG) or glucose. The formation method includes chemically reacting silver nitrate with a reducing agent to form a silver nanoparticle conjugated to the reducing agent of a GAG or glucose. The application method may include topically applying the silver nanocomposite to a wound or burn as an anti-microbial with respect to an antibiotic-resistant genotype in the wound or burn, wherein the silver nanocomposite topically applied includes the silver nanoparticle conjugated to the GAG of 2,6-diaminopyridinyl heparin (DAPHP) or hyaluronan (HA). The application method may include applying the silver nanocomposite as a coating to plastic, a catheter, or a surgical tool, wherein the silver nanocomposite applied as the coating includes the silver nanoparticle conjugated to the GAG of DAPHP.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: November 20, 2012
    Assignee: Vascular Vision Pharmaceutical Co.
    Inventors: Shaker A. Mousa, Robert J. Linhardt
  • Patent number: 8314070
    Abstract: This invention relates to certain Aloesin derivatives with natural amino acids, peptides, and amino sugars (formula I).
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: November 20, 2012
    Assignee: Island Kinetics, Inc.
    Inventors: Shyam K Gupta, Linda Walker
  • Publication number: 20120276108
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of glycolysis, inhibitors of protein glycosylation, anti-virals, and down-regulators of insulin receptor and IGF-1 receptor for the treatment or prevention of inflammatory dermatological diseases or proliferative dermatological diseases.
    Type: Application
    Filed: January 11, 2012
    Publication date: November 1, 2012
    Applicant: INTERTECH BIO
    Inventor: Waldemar Priebe
  • Publication number: 20120264929
    Abstract: The present invention relates to a novel process for producing N-acetyl-D-Glucosamine from Glucosamine hydrochloride. More particularly this invention pertains to a novel and simple environmentally acceptable process for producing glucosamine base solution in water, with very low halide content. Glucosamine base in solution with >95% chloride ion removal is further reacted with acylating agent to produce N-acetyl-D-Glucosamine with >99% purity and chloride content of <0.1%.
    Type: Application
    Filed: November 23, 2009
    Publication date: October 18, 2012
    Inventors: Mahesh Devdhar, Trupti Darge
  • Patent number: 8288527
    Abstract: An oligo-aminosaccharide compound formed by binding 3 to 6 saccharides, such as 2,6-diamino-2,6-dideoxy-?-(1?4)-D-glucopyranose oligomers, or a salt thereof, which has high affinity to a double-stranded nucleic acid.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: October 16, 2012
    Assignee: The University of Tokyo
    Inventors: Takeshi Wada, Rintaro Iwata
  • Patent number: 8283463
    Abstract: A process for sterilizing a solution comprising hyaluronic acid. The process comprises providing an aqueous solution of hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and the concentration of the hyaluronic acid is from 0.04% to 0.8% by weight. The aqueous solution also has an ionic strength equivalent to an aqueous concentration of sodium chloride from 3% to 30% by weight. Once the aqueous, high salt, hyaluronic acid solution is prepared the solution is maintained at a temperature from 40° C. to 80° C. for at least 1 hour and not longer than six days. Following the heat treatment step, the aqueous solution is filtered through a sterilization filter medium to provide a sterilized high salt, hyaluronic acid solution.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: October 9, 2012
    Assignee: Bausch & Lomb Incorporated
    Inventors: X. Michael Liu, David J. Heiler, Thomas Menzel, Abbie Brongo, Susan E. Burke, Karl Cummins
  • Patent number: 8268950
    Abstract: Polymers comprising glucosamine (GlcN) are used to make medical devices. Examples include polyGlcN and carrier molecules containing multiple GlcN residues.
    Type: Grant
    Filed: February 10, 2009
    Date of Patent: September 18, 2012
    Assignee: The Johns Hopkins University
    Inventor: Jennifer H. Elisseeff
  • Patent number: 8247381
    Abstract: The present invention provides branched water-soluble polymers that allow two or more water-soluble polymers to be conjugated to another species. The branched polymers provide access to therapeutic agents that are conjugated at a single site to two or more water-soluble polymers. The branched polymers are based upon branch points that are simple branched alkyl structures, reactive side-chain amino acids and small peptides of reactive side-chain amino acids, and saccharides. Also provided is a method for preparing mono-disperse poly(ethylene glycol) of a well-defined and determinable molecular weight, and a method for the rational end-functionalization of poly(ethylene glycol). Conjugates of the branched water-soluble polymers with diverse species, e.g., peptides, lipids, glycolipids and small molecules are also provided.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: August 21, 2012
    Assignee: BioGeneriX AG
    Inventor: Shawn DeFrees
  • Publication number: 20120156137
    Abstract: Disclosed herein is a novel use of glucosamine or a derivative thereof. A pharmaceutical composition for treating atopic dermatitis comprising glucosamine or a derivative thereof and a method of treating atopic dermatitis using the composition are disclosed. The pharmaceutical composition and the method realize the safe treatment of atopic dermatitis without the side effects associated with conventional anti-inflammatory drugs.
    Type: Application
    Filed: October 19, 2007
    Publication date: June 21, 2012
    Inventors: Soo-youl Kim, Chang-hoon Lee, Ai-young Lee
  • Patent number: 8202986
    Abstract: A branched hyaluronic acid, wherein the linear backbone comprises hyaluronic acid in which one or more N-Acetyl-Glucosamine has been deacetylated to Glucosamine, with branching sidechain(s) covalently linked to the primary amine(s) of said deacetylated Glucosamine thus forming a secondary amine(s); a precursor for producing said branched hyaluronic acid; and a method for producing said branching hyaluronic acid.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: June 19, 2012
    Assignee: Novozymes Biopolymer AIS
    Inventors: Kristoffer Toemmeraas, Khadija Schwach-Abdellaoui
  • Patent number: 8202971
    Abstract: A process for preparing compounds of chitosan saccharified with aminosugar, adopts chitosan derivatives, aminosugar derivatives and anhydride derivatives as raw materials to synthesize target products. The process comprises: covalently bonding an anhydride derivative as a bonding arm to an aminosugar derivative, so as to form a monosaccharide derivative having an end group of carboxyl; and then covalently bonding the monosaccharide derivative having an end group of carboxyl to a primary amino group of a chitosan derivative via the carboxyl, so as to form a compound of chitosan saccharified with aminosugar.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: June 19, 2012
    Assignee: Ocean University of China
    Inventors: Xiguang Chen, Jing Li, Xiaojie Cheng, Tao Jiang
  • Patent number: 8198420
    Abstract: The present invention relates to synthetic compounds that are active on plants, especially as legume nodulation factors, and also as plant growth stimulators, and to methods for preparing such compounds, which are of formula (I).
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: June 12, 2012
    Assignees: Bayer SAS, Institute National de la Recherche Agronomique, Centre National de la Recherche Scientifique
    Inventors: Jean-Marie Beau, Jean Denarie, Alfred Grenier, Nathalie Grenouillat, Fabienne Maillet, Boris Vauzeilles